Graziani, Silvia Regina; Vital, Carolina Graziani; Morikawa, Aleksandra Tiemi; Eyll, Brigitte M. Van; Fernandes Júnior, Hézio Jadir; Kalil Filho, Roberto; Maranhão, Raul Cavalcante 
Source: Medical Oncology. Unidades: FM, FCF
Subjects: NANOPARTÍCULAS, CARCINOMA, OVÁRIO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GRAZIANI, Silvia Regina et al. Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma. Medical Oncology, v. 34, p. 1-7 art. 151, 2017Tradução . . Disponível em: https://doi.org/10.1007/s12032-017-1009-z. Acesso em: 09 maio 2024.APA
Graziani, S. R., Vital, C. G., Morikawa, A. T., Eyll, B. M. V., Fernandes Júnior, H. J., Kalil Filho, R., & Maranhão, R. C. (2017). Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma. Medical Oncology, 34, 1-7 art. 151. doi:10.1007/s12032-017-1009-zNLM
Graziani SR, Vital CG, Morikawa AT, Eyll BMV, Fernandes Júnior HJ, Kalil Filho R, Maranhão RC. Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma [Internet]. Medical Oncology. 2017 ; 34 1-7 art. 151.[citado 2024 maio 09 ] Available from: https://doi.org/10.1007/s12032-017-1009-zVancouver
Graziani SR, Vital CG, Morikawa AT, Eyll BMV, Fernandes Júnior HJ, Kalil Filho R, Maranhão RC. Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma [Internet]. Medical Oncology. 2017 ; 34 1-7 art. 151.[citado 2024 maio 09 ] Available from: https://doi.org/10.1007/s12032-017-1009-z
